Clinical characteristics of the study patients with systemic sclerosis.
| Population | Netherlands | Spain | Germany | Sweden | Italy |
|---|---|---|---|---|---|
| No. | 143 | 231 | 422 | 161 | 444 |
| Age, yrs (SD) | 56 (13) | 55 (13) | 57 (12) | 53 (15) | 54 (13) |
| Disease duration, mo (SD) | 132 (87) | 143 (90) | 112 (109) | 83 (73) | 146 (138) |
| Women, % | 73.2 | 83.8 | 83.2 | 78.8 | 89.0 |
| Limited phenotype, % | 74.8 | 73.7 | 61.2 | 72.0 | 74.4 |
| ANA-positive, % | 73.2 | 85.4 | 83.2 | 75.1 | 81.6 |
| Anti-topo I-positive, % | 22 | NA | 24.8 | 16.7 | 25.2 |
| ACA-positive, % | 26.8 | 46.7 | 41.3 | 26.1 | 47.1 |
| Controls | |||||
| Age, yrs (SD) | 45 (12) | 56 (14) | 48 (9) | 52 (11) | 52 (14) |
| Women, % | 69.3 | 85.1 | 82.4 | 80.2 | 85.0 |
ANA: antinuclear antibodies; anti-topo I: antitopoisomerase I antibodies; ACA: anticentromere antibodies.